Manju George MVSc PhD · @manjuggm
72 followers · 407 posts · Server med-mastodon.comRT @OncBrothers@twitter.com
Day 3 #GI23 Highlights #CommunityOncology
1. #MOUNTAINEER: Tucat+Trast approved CRC
2. #SUNLIGHT: TAS102+Bev confirmed late option CRC
3. #E2211: Cape+Tem in pNET manuscript
4. #ctDNA kinetics CRC
5. TNT state in RectalCA
@ASCO@twitter.com #OncEd #MedEd @OncoAlert@twitter.com #GISM #MedTwitter
🐦🔗: https://twitter.com/OncBrothers/status/1616940781562134534
#gi23 #communityoncology #mountaineer #sunlight #e2211 #ctDNA #OncEd #MedEd #gism #medtwitter
Manju George MVSc PhD · @manjuggm
73 followers · 388 posts · Server med-mastodon.comRT @OncBrothers@twitter.com
Day 1 #GI23 Highlights #CommunityOncology
1. #NeoAGIS: Chemo vs CROSS
2. #Infinity: NeoAdj IO dMMR G/GEJ Ca
3. #SPOTLIGHT: CLDN18.2 (Importance of NGS)- New SoC
4. #INTEGRATEIIA: Rego in pretreated pts
@ASCO@twitter.com #OncEd #MedEd #Oncology @OncoAlert@twitter.com @HemOncFellows@twitter.com #gism
🐦🔗: https://twitter.com/OncBrothers/status/1616211370411970561
#gi23 #communityoncology #neoagis #infinity #Spotlight #integrateiia #OncEd #MedEd #oncology #gism
Manju George MVSc PhD · @manjuggm
73 followers · 332 posts · Server med-mastodon.comRT @OncBrothers@twitter.com
To get the stage ready for upcoming GI @ASCO@twitter.com & to understand 1 of the most pivotal studies of 2022, we discuss #NICHE2 w/ @MyriamChalabi@twitter.com from @NKI_nl@twitter.com
Full Int:
- https://oncbrothers.com/journalclub-niche2/
- Also on “Oncology Brothers” podcast
#OncJC #MedTwitter #OncEd #GISM #ChalabiPlot #GI23
🐦🔗: https://twitter.com/OncBrothers/status/1615002038726807553
#niche2 #oncjc #medtwitter #OncEd #gism #chalabiplot #gi23
Erika Hamilton, MD · @ErikaHamilton9
75 followers · 249 posts · Server med-mastodon.com
RT @OncBrothers@twitter.com
3 new drugs/indications were approved by @FDAOncology@twitter.com for Breast Cancer and 2 for Gyn Onc in 2022. Here is a summary!
- #TDXd x 2
- #Olaparib
- #Pembrolizumab
- #Mirvetuximab
#bcsm #gynsm @OncoAlert@twitter.com #breastcancer #MedTwitter #OncEd #MedEd #ovariancancer
🐦🔗: https://twitter.com/OncBrothers/status/1607753014521262081
#tdxd #olaparib #pembrolizumab #Mirvetuximab #bcsm #GYNSM #breastcancer #medtwitter #OncEd #MedEd #ovariancancer
Oncology Brothers · @OncBrothers
36 followers · 8 posts · Server med-mastodon.com
Treatment for Upper GI is rapidly evolving, Dr. Rutika Mehta from Moffitt Cancer Center walks us through the rx algorithm to reiterate the current SoC in the community:
- m.youtube.com/watch?v=tTnsmS…
- oncbrothers.com/uppergi-mehta-…
- Also on “Oncology Brothers” podcast
#gism #MedMastodon #OncEd #CME #oncology #cancer
Oncology Brothers · @OncBrothers
35 followers · 7 posts · Server med-mastodon.com
2 weeks to @SABCS, here is a list of our "top" anticipated practice-informing studies for the community onc. Looking forward to accredited conference highlights with our expert faculty after #SABCS22
#SABCS22 #bcsm #MedMastodon #OncEd #MedEd #breastcancer #oncology
Oncology Brothers · @OncBrothers
33 followers · 6 posts · Server med-mastodon.com
#Belantamab is being WITHDRAWN as a Rx for refractory multiple myeloma (accelerated approval in August 2020 off #DREAMM2).
#DREAMM3: Ph3,N=320, belanta vs Pom/Dex after ≥2 Rx.
- No PFS/OS benefit
- similar ORR
- Belanta had ophthalmologic AEs
#belantamab #dreamm2 #dreamm3 #mmsm #bcma #OncEd #oncology #MedMastodon #myeloma
Oncology Brothers · @OncBrothers
15 followers · 3 posts · Server med-mastodon.com
To complete our #BreastCancer series, Dr. Shipra Gandhi from Roswell Park Comprehensive Cancer Center walks us through the TNBC algorithm to reiterate the current SoC in the community.
- youtu.be/RmurBk_qIxE
- oncbrothers.com/tnbc-gandhi-20…
- Also on “Oncology Brothers” podcast
#breastcancer #bcsm #OncEd #SABCS22 #cancer
Oncology Brothers · @OncBrothers
12 followers · 2 posts · Server med-mastodon.com
#Mirvetuximab soravtansine-gynx now #FDA approved for FRα +ve, platinum-resistant epithelial ovarian, Fallopian tube, or 1° peritoneal Ca post 1-3L of Rx.
- Assay-Ventana FOLR1 (FOLR-2.1)
- #SORAYA: Ph3, n=106, ORR 31.7%, CR:4.8%, mDOR of 6.9 mos
#Mirvetuximab #FDA #SORAYA #oncology #OncEd #GYNSM #CME #AntibodyDrugConjugate